Literature DB >> 12401444

Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination.

Hardy J Rideout1, Leonidas Stefanis.   

Abstract

Increasing evidence suggests that proteasomal dysfunction plays a role in the pathogenesis of Lewy body diseases. We have used pharmacological inhibitors of the proteasome to model proteasomal dysfunction in cultured rat cortical neurons. Proteasomal inhibition induced apoptotic death and formation of cytoplasmic ubiquitinated inclusions, which were present only in viable neurons. Actinomycin D, but not a caspase inhibitor, prevented inclusion formation, whereas both agents inhibited cell death. alpha-Synuclein and thioflavin S staining were found within the inclusions. alpha-Synuclein, however, did not appear to be ubiquitinated or aggregated. A dominant-negative mutant of an E2 ubiquitin-conjugating enzyme, cdc34, prevented inclusion formation and attenuated cell death. Our results suggest that in cortical neurons: (a) proteasomal dysfunction plays a role in formation of ubiquitin/alpha-synuclein-positive inclusions, (b) inclusion formation is an active cell process requiring transcription, and (c) ubiquitination of certain proteins is required for inclusion formation and may participate in neuronal death.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401444     DOI: 10.1006/mcne.2002.1173

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  34 in total

Review 1.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

2.  Neuroprotective upregulation of endogenous α-synuclein precedes ubiquitination in cultured dopaminergic neurons.

Authors:  R E J Musgrove; A E King; T C Dickson
Journal:  Neurotox Res       Date:  2010-07-09       Impact factor: 3.911

3.  Characterization of Puma-dependent and Puma-independent neuronal cell death pathways following prolonged proteasomal inhibition.

Authors:  Liam P Tuffy; Caoimhín G Concannon; Beatrice D'Orsi; Matthew A King; Ina Woods; Heinrich J Huber; Manus W Ward; Jochen H M Prehn
Journal:  Mol Cell Biol       Date:  2010-10-04       Impact factor: 4.272

Review 4.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

5.  Astrocytes Surviving Severe Stress Can Still Protect Neighboring Neurons from Proteotoxic Injury.

Authors:  Amanda M Gleixner; Jessica M Posimo; Deepti B Pant; Matthew P Henderson; Rehana K Leak
Journal:  Mol Neurobiol       Date:  2015-09-15       Impact factor: 5.590

6.  Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture.

Authors:  Natasha Bajic; Peter Jenner; Clive G Ballard; Paul T Francis
Journal:  J Neural Transm (Vienna)       Date:  2012-05-17       Impact factor: 3.575

7.  Complex Effects of the ZSCAN21 Transcription Factor on Transcriptional Regulation of α-Synuclein in Primary Neuronal Cultures and in Vivo.

Authors:  Georgia Dermentzaki; Nikolaos Paschalidis; Panagiotis K Politis; Leonidas Stefanis
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

8.  Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells.

Authors:  Tereza Vogiatzi; Maria Xilouri; Kostas Vekrellis; Leonidas Stefanis
Journal:  J Biol Chem       Date:  2008-06-19       Impact factor: 5.157

Review 9.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

10.  Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy.

Authors:  Maria Xilouri; Tereza Vogiatzi; Kostas Vekrellis; David Park; Leonidas Stefanis
Journal:  PLoS One       Date:  2009-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.